Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Xenon ( (XENE) ) is now available.
Xenon Pharmaceuticals has priced an upsized underwritten public offering of 10,526,317 common shares and pre-funded warrants for 877,194 shares at about $57 per share, targeting gross proceeds of roughly $650 million before expenses. The deal, led by a syndicate including J.P. Morgan, Jefferies, TD Cowen and others, includes a 30-day option for underwriters to buy an additional 1,710,526 shares and is expected to close around March 12, 2026, bolstering Xenon’s capital base for its neuroscience pipeline while excluding Canadian investors.
The offering is conducted under an effective shelf registration with the U.S. Securities and Exchange Commission, with distribution solely via a filed prospectus and supplement. By successfully upsizing and executing this large equity raise in U.S. markets, Xenon reinforces its access to public capital and strengthens its financial flexibility for ongoing and future drug development, which could enhance its competitive position in the biopharmaceutical sector.
The most recent analyst rating on (XENE) stock is a Buy with a $90.00 price target. To see the full list of analyst forecasts on Xenon stock, see the XENE Stock Forecast page.
Spark’s Take on XENE Stock
According to Spark, TipRanks’ AI Analyst, XENE is a Neutral.
The score is driven by a strong balance sheet/runway and constructive pipeline progress and guidance from the earnings call, partially offset by substantial and rising losses with heavy cash burn and limited valuation support due to negative earnings.
To see Spark’s full report on XENE stock, click here.
More about Xenon
Xenon Pharmaceuticals Inc., listed on Nasdaq as XENE, is a neuroscience-focused biopharmaceutical company engaged in the discovery, clinical development and commercialization of therapeutics for patients with unmet medical needs. Operating from Vancouver and Boston, the company is centered on developing life-changing drugs targeting neurological conditions and related disorders.
Average Trading Volume: 1,099,694
Technical Sentiment Signal: Buy
Current Market Cap: $5.22B
See more insights into XENE stock on TipRanks’ Stock Analysis page.